MediciNova (4875) News

Jason McCarthy Reiterates Buy on MediciNova, Maintains $6 Price Target Ahead of Key ALS and Metabolic Disease Readouts

TipRanksAug 15 22:55 · Ratings

Analyst Reiterates Buy on MediciNova With Unchanged $10 Price Target Amid Progress of Lead Clinical Programs

TipRanksAug 14 18:26

MediciNova: Interim Financial Results for the Second Quarter (Half-Year) of Fiscal Year Ending December 2026 (U.S. GAAP, Consolidated)

JPXAug 14 07:00 · Announcements

MediciNova | 10-Q: Quarterly report

SECAug 14 04:31 · Announcements

Earnings Preview: MediciNova to Report Financial Results Post-market on August 14

$MediciNova(MNOV.US)$ is scheduled to release its financial results post-market on August 14 ET. Earnings PreviewAnalysts estimate $MediciNova(MNOV.US)$ to post revenue of USD75000.00 for 2026Q2,

Futu NewsAug 11 09:00

MediciNova: Differentiated NAFLD/MASH Profile and Complementary APOC3 Positioning Support Unchanged $6 Target and Buy Rating

TipRanksJul 24 05:25 · Ratings

Analysts Offer Insights on Healthcare Companies: Medicinova (MNOV), Legend Biotech (LEGN) and AngioDynamics (ANGO)

TipRanksJul 16 00:30 · Ratings

Express News | Medicinova Announces Patient Enrollment Milestone Achieved in Seanobi Study Expanded-Access-Program Evaluating Mn‑166 (Ibudilast) in ALS Patients

BreakingsJul 15 20:00

Analyst Reiterates Buy on MediciNova as Advancing Pipeline and Upcoming ALS Catalysts Support Unchanged $6 Price Target

TipRanksJul 2 03:35

Express News | Medicinova CEO Provides Shareholder Update

BreakingsJun 30 20:00

MediciNova: Interim Report

EDINETJun 30 14:30 · Announcements

MediciNova Shareholders Reject Proposal to Increase Authorized Stock

TipRanksJun 25 04:57

MediciNova: Confirmation Letter

EDINETJun 17 12:37 · Announcements

MediciNova: Securities Report

EDINETJun 17 12:36 · Announcements

MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma

BenzingaJun 8 20:07

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination With Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

GlobeNewswireJun 8 20:00

Analysts' Top Healthcare Picks: Coherus Biosciences (CHRS), Medicinova (MNOV)

TipRanksMay 29 03:20 · Ratings

H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10

Futu NewsMay 28 16:31 · Ratings

Analyst Initiates Buy on MediciNova, Citing Pivotal Tipelukast and Ibudilast Catalysts to Support $10 Price Target

TipRanksMay 28 15:55

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewswireMay 27 07:00